Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dacogen

- PMLiVE

Perrigo agrees $8.6bn deal to buy Elan

Ends months of speculation about fate of Irish pharma company

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

Ipsen strengthens neurology efforts with Syntaxin purchase

French pharma firm also agrees research deal with Harvard

- PMLiVE

Analysts question value of rumoured $20bn Roche bid for Alexion

Shares in orphan drug specialist slide back after earlier surge

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

Deal Watch table for June 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links